Investor Relations

Listed On The Shanghai Stock Exchange In June 2001, With A Maximum Market Value Of 47.5 Billion

Ad hoc announcement pursuant to Art-JCARE Announcement on Obtaining the Approval Notice for Drug Clinical Trials

Time:2023-10-13

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Third Extraordinary General Meeting

Time:2023-10-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Third Extraordinary General Meeting

Time:2023-09-21

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resolutions of 2023 Sencond Extraordinary General Meeting

Time:2023-09-15

Ad hoc announcement pursuant to Art-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for Aripiprazole Microspheres for Injection

Time:2023-09-12

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Appointment of Vice President of The Company

Time:2023-09-08

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on the Acceptance of the Application for Marketing Authorization for the New Indication of Triptorelin Acetate Microspheres for Injection

Time:2023-08-24

Ad hoc announcement pursuant to Art. 53 LR-JCARE Notice of 2023 Second Extraordinary General Meeting

Time:2023-08-23

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Resignation of Independent Director and By-election of Independent Director

Time:2023-08-23

Ad hoc announcement pursuant to Art. 53 LR-JCARE Announcement on Approval for Registration of Blonanserin Tablets

Time:2023-08-11

< 1...111213...16 >